SI2579894T1 - Cgrp protitelesa - Google Patents
Cgrp protitelesa Download PDFInfo
- Publication number
- SI2579894T1 SI2579894T1 SI201131359T SI201131359T SI2579894T1 SI 2579894 T1 SI2579894 T1 SI 2579894T1 SI 201131359 T SI201131359 T SI 201131359T SI 201131359 T SI201131359 T SI 201131359T SI 2579894 T1 SI2579894 T1 SI 2579894T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- amino acid
- human
- genetic engineering
- acid sequence
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims abstract 13
- 239000000427 antigen Substances 0.000 claims abstract 3
- 108091007433 antigens Proteins 0.000 claims abstract 3
- 102000036639 antigens Human genes 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims abstract 3
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000010353 genetic engineering Methods 0.000 claims 7
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 4
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (8)
- CGRP PROTITELESA Patentni zahtevki1. Človeško z genskim inženiringom narejeno CGRP protitelo, ki vključuje variabilno regijo lahke verige (LCVR) in variabilno regijo težke verige (HCVR), pri čemer omenjena LCVR vključuje LCDR1, LCDR2, LCDR3 aminokislinska zaporedja in HCVR vključuje HCDR1, HCDR2, HCDR3 aminokislinska zaporedja, kjer je LCDR1 je RASKDISKYLN (SEQ ID NO: 6), LCDR2 je YTSGYHS (SEQ ID NO: 7), LCDR3 je QQGDALPPT (SEQ ID NO: 5), HCDR1 je GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 je AIYEGTGKTVYIQKFAD (SEQ ID NO: 16), in HCDR3 je LSDYVSGFGY (SEQ ID NO: 39).
- 2. Človeško z genskim inženiringom narejeno CGRP protitelo po zahtevku 1, kjer je aminokislinsko zaporedje omenjene LCVR SEQ ID NO: 19 in je aminokislinsko zaporedje omenjene HCVR SEQ ID NO: 24.
- 3. Človeško z genskim inženiringom narejeno CGRP protitelo po zahtevku 2, kjer omenjeno protitelo vključuje lahko verigo in težko verigo, pri čemer je aminokislinsko zaporedje lahke verige SEQ ID NO: 29 in je aminokislinsko zaporedje težke verige SEQ ID NO: 34.
- 4. Človeško z genskim inženiringom narejeno CGRP protitelo po zahtevku 3, kjer omenjeno protitelo vključuje dve lahki verigi in dve težki verigi, pri čemer je aminokislinsko zaporedje vsake lahke verige SEQ ID NO: 29 in je aminokislinsko zaporedje vsake težke verige SEQ ID NO: 34.
- 5. Farmacevtska zmes, ki vsebuje človeško z genskim inženiringom narejeno CGRP protitelo po kateremkoli izmed zahtevkov od 1 do 4 in farmacevtsko sprejemljiv nosilec, razredčilo ali pomožno snov.
- 6. Človeško z genskim inženiringom narejeno CGRP protitelo po kateremkoli izmed zahtevkov od 1 do 4 za uporabo v terapiji.
- 7. Človeško z genskim inženiringom narejeno CGRP protitelo po kateremkoli izmed zahtevkov od 1 do 4 za uporabo pri zdravljenju migren.
- 8. Fragment, ki veže antigen, človeškega z genskim inženiringom narejenega CGRP protitelesa po kateremkoli izmed zahtevkov od 1 do 4 ali 6 do 7.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35332310P | 2010-06-10 | 2010-06-10 | |
EP11792989.3A EP2579894B1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
PCT/US2011/039381 WO2011156324A1 (en) | 2010-06-10 | 2011-06-07 | Cgrp antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2579894T1 true SI2579894T1 (sl) | 2018-01-31 |
Family
ID=45096388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201131359T SI2579894T1 (sl) | 2010-06-10 | 2011-06-07 | Cgrp protitelesa |
Country Status (34)
Country | Link |
---|---|
US (3) | US9073991B2 (sl) |
EP (2) | EP2579894B1 (sl) |
JP (2) | JP6021806B2 (sl) |
KR (1) | KR101489566B1 (sl) |
CN (2) | CN102946905B (sl) |
AR (1) | AR081434A1 (sl) |
AU (1) | AU2011265050B2 (sl) |
BR (1) | BR112012031501B1 (sl) |
CA (1) | CA2802102C (sl) |
CY (2) | CY1119789T1 (sl) |
DK (1) | DK2579894T3 (sl) |
EA (1) | EA022931B1 (sl) |
ES (2) | ES2656000T3 (sl) |
HK (1) | HK1203211A1 (sl) |
HR (1) | HRP20171992T1 (sl) |
HU (2) | HUE038135T2 (sl) |
IL (2) | IL222885B (sl) |
JO (1) | JO3330B1 (sl) |
LT (2) | LT2579894T (sl) |
LU (1) | LUC00112I2 (sl) |
ME (1) | ME02862B (sl) |
MX (2) | MX363209B (sl) |
NL (1) | NL300979I2 (sl) |
NO (2) | NO2579894T3 (sl) |
NZ (1) | NZ603607A (sl) |
PL (1) | PL2579894T3 (sl) |
PT (1) | PT2579894T (sl) |
RS (1) | RS56638B1 (sl) |
SG (1) | SG185648A1 (sl) |
SI (1) | SI2579894T1 (sl) |
TW (1) | TWI423818B (sl) |
UA (1) | UA109658C2 (sl) |
WO (1) | WO2011156324A1 (sl) |
ZA (1) | ZA201208996B (sl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2380592T3 (pl) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals International Gmbh | Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny |
WO2009109911A1 (en) | 2008-03-04 | 2009-09-11 | Pfizer Limited | Methods of treating chronic pain |
RU2535074C2 (ru) | 2009-08-28 | 2014-12-10 | Лэйбрис Байолоджикс, Инк. | Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина |
AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
US9708393B2 (en) | 2011-05-20 | 2017-07-18 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
CN107602700B (zh) | 2011-05-20 | 2021-12-17 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
MX365813B (es) | 2011-05-20 | 2019-06-14 | Alderbio Holdings Llc | Uso de anticuerpos anti-cgrp o anti-cgrp o fragmentos de anticuerpo para tratar o prevenir formas crónicas y agudas de diarrea. |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
US10556945B2 (en) * | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
LT3119431T (lt) | 2014-03-21 | 2024-03-12 | Teva Pharmaceuticals International Gmbh | Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai |
EP3825324A1 (en) | 2014-10-24 | 2021-05-26 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
WO2017074428A1 (en) * | 2015-10-30 | 2017-05-04 | Eli Lilly And Company | Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof |
CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
US20190031748A1 (en) * | 2016-01-28 | 2019-01-31 | Eli Lilly And Company | Cgrp antibodies and uses thereof |
AU2017214277B2 (en) | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
KR20240113990A (ko) | 2016-06-27 | 2024-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
US20180111984A1 (en) | 2016-09-23 | 2018-04-26 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
JP7195262B2 (ja) * | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
TW201902926A (zh) | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp/抗il-23雙特異性抗體及其用途 |
WO2018237159A1 (en) * | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY |
TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
MX2020006976A (es) | 2018-01-12 | 2020-10-05 | Amgen Inc | Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos. |
WO2019231800A1 (en) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
JP2021534197A (ja) | 2018-08-22 | 2021-12-09 | イーライ リリー アンド カンパニー | 治療抵抗性患者のための抗cgrp抗体 |
CA3123237A1 (en) | 2019-01-08 | 2020-07-16 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
EP3744400A1 (en) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
CN114127110B (zh) * | 2019-05-30 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗cgrp抗体及其应用 |
JP2022552323A (ja) | 2019-10-15 | 2022-12-15 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ/エステラーゼ欠損哺乳動物細胞株 |
WO2022185224A1 (en) | 2021-03-02 | 2022-09-09 | Mark Hasleton | Treatment and/or reduction of occurrence of migraine |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
WO2024032750A1 (zh) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | 抗cgrp抗体及用途 |
CN118271438B (zh) * | 2024-05-27 | 2024-08-30 | 上海宏成药业有限公司 | 抗cgrp抗体或其抗原结合片段及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
ES2206447T3 (es) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
EP1885402A4 (en) * | 2005-04-08 | 2010-11-10 | Medimmune Inc | ANTIBODIES AGAINST METAPNEUMOVIRUS FROM MAMMALS |
PL2380592T3 (pl) * | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals International Gmbh | Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny |
WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
CA2716799C (en) * | 2008-03-04 | 2018-05-22 | Pfizer Limited | Methods of treating inflammatory pain |
WO2009109911A1 (en) * | 2008-03-04 | 2009-09-11 | Pfizer Limited | Methods of treating chronic pain |
AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
-
2011
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en active Application Filing
- 2011-06-07 SI SI201131359T patent/SI2579894T1/sl unknown
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active IP Right Grant
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-04-20 HK HK15103793.6A patent/HK1203211A1/xx unknown
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2017
- 2017-12-21 HR HRP20171992TT patent/HRP20171992T1/hr unknown
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-02 CY CY2019017C patent/CY2019017I1/el unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2579894T1 (sl) | Cgrp protitelesa | |
JP2022177090A5 (sl) | ||
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
SI3042917T1 (sl) | Protitelesa proti n3pglu amiloid beta peptidu in njihova uporaba | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
JP2012523417A5 (sl) | ||
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
NZ610734A (en) | Human antibodies to the glucagon receptor | |
NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
JP2013542194A5 (sl) | ||
JP2015514110A5 (sl) | ||
MX353931B (es) | Anticuerpos que se unen a ox40 y sus usos. | |
NZ597466A (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
NZ598063A (en) | Gram-positive bacteria specific binding compounds | |
RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies |